Traws Pharma, Inc. filed a Form S-1 registration statement with the SEC on October 26, 2026, covering the potential resale of up to 135,135,135 shares of common stock by selling stockholder Roth Principal Investments, LLC, under a committed equity facility established by a purchase agreement dated October 23, 2026.

Key Highlights

  • Shares registered: Up to 135,135,135 shares of common stock, par value $0.01 per share, are covered by this prospectus for resale by Roth Principal Investments, LLC.
  • Maximum gross proceeds to company: Traws Pharma may receive up to $50,000,000 aggregate gross proceeds (subject to certain limitations) from sales made to Roth Principal Investments under the Purchase Agreement.
  • No shares sold yet: According to the filing, as of the date of the prospectus, no shares of common stock covered by the prospectus had been sold to Roth Principal Investments under the Purchase Agreement.
  • Stock price at filing: The closing price of Traws Pharma common stock on October 23, 2026 was $0.34 per share, as disclosed in the prospectus.
  • Independent underwriter fee: The company disclosed it agreed to pay Compass Point Research and Trading LLC a cash fee of $50,000 to act as a "qualified independent underwriter" in this offering.
  • Company classification: The filing identifies Traws Pharma as a non-accelerated filer and a smaller reporting company, subject to reduced public company reporting requirements.

Traws Pharma Registers Committed Equity Facility Linked to Roth Principal Investments

Traws Pharma, Inc., whose common stock is listed on The Nasdaq Capital Market under the symbol NASDAQ:TRAW, filed the S-1 registration statement to register the resale of up to 135,135,135 shares of common stock by Roth Principal Investments, LLC. The shares are connected to a Common Stock Purchase Agreement dated October 23, 2026, which the filing describes as a "Committed Equity Facility." Under that agreement, the company disclosed it may, in its sole discretion, elect to issue and sell shares to Roth Principal Investments from time to time, subject to the terms of the Purchase Agreement.

The filing states that the company "will control the timing and amount of any sales of Common Stock to Roth Principal Investments" and that actual sales "will depend on a variety of factors to be determined by us from time to time, which may include, without limitation, market conditions, the trading price of the Common Stock, and determinations by us as to the appropriate sources of funding for our business and operations." The company also noted that "there can be no assurances" that it will choose to sell any shares, or that Roth Principal Investments will sell any shares purchased, under the Purchase Agreement.

According to the filing, Traws Pharma will not receive any proceeds from the resale of shares by the Selling Stockholder. The Selling Stockholder is identified as an "underwriter" within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended. The Selling Stockholder will bear all brokerage fees, commissions, and similar expenses related to the resale, while the company will pay registration-related expenses including legal and accounting fees. The company is incorporated in Delaware, classified under SIC code 2834, and maintains its principal offices at 12 Penns Trail, Newtown, PA 18940.

What Was Disclosed

Traws Pharma filed a Form S-1 on October 26, 2026, registering up to 135,135,135 shares of common stock for resale by Roth Principal Investments, LLC, under a purchase agreement that allows the company to raise up to $50,000,000 in gross proceeds at its discretion.